AEON · XBRL financial data
AEON Biopharma financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (AEON's year ends in late December)
| In thousands of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|
| Research and development | — | 34,754 | — | 14,181 | 4,094 |
| Selling, general and administrative | — | 13,675 | — | 13,643 | 12,208 |
| Total operating expenses | — | 48,429 | — | (72,985) | 12,803 |
| Operating income (loss) | (1,936) | (3,326) | — | 72,985 | (12,803) |
| Interest income | 80 | 3,707 | — | — | — |
| Other income (expense) | — | 289 | — | 95 | 290 |
| Income tax expense (benefit) | — | 883 | — | 0 | 0 |
| Net income (loss) | 8,201 | 6,375 | — | 42,005 | (39,222) |
| Earnings per share, basic‡ USD per share | — | (27.36) | — | 5,596.83 | (3.95) |
| Earnings per share, diluted‡ USD per share | — | (27.36) | — | 5,250.54 | (3.95) |
| Weighted average shares, basic‡ thousands of shares | — | 1,929 | — | 8 | 9,922 |
| Weighted average shares, diluted‡ thousands of shares | — | 1,929 | — | 8 | 9,922 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-71.99424046076314 stock split (February 2025); filings made before it reported them unadjusted.
- † Share count changed about 173x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (AEON's year ends in late December)
| In thousands of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 497 | 9,746 | 5,158 | 13 | 3,006 |
| Prepaid and other current assets | — | 92 | 1,064 | 1,577 | 392 |
| Total current assets | 835 | 109 | 6,222 | 1,590 | 3,398 |
| Property and equipment, net | — | 431 | 332 | 235 | 162 |
| Right-of-use asset | — | 475 | 262 | 1,288 | 1,052 |
| Total assets | 276,950 | 279,494 | 6,845 | 3,142 | 5,560 |
| Accounts payable | — | 7,805 | 3,388 | 5,910 | 942 |
| Total current liabilities | 835 | 3,881 | 13,049 | 14,149 | 6,897 |
| Lease liability, non-current | — | 242 | — | 1,145 | 893 |
| Total liabilities | 17,879 | 10,443 | 159,889 | 31,711 | 60,587 |
| Accumulated deficit | (16,963) | (9,470) | (473,602) | (431,597) | (470,819) |
| Total stockholders' equity | (16,930) | (9,437) | (153,044) | (28,569) | (55,027) |
| Total liabilities and equity | 276,950 | 279,494 | 6,845 | 3,142 | 5,560 |
| Common shares outstanding (cover page)‡ thousands of shares | — | 1,928 | 525 | 146 | 25,303 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-71.99424046076314 stock split (February 2025); filings made before it reported them unadjusted.
- † Share count changed about 173x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (AEON's year ends in late December)
| In thousands of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|
| Net income (loss) | 8,201 | 6,375 | — | 42,005 | (39,222) |
| Stock-based compensation | — | 5,892 | — | 6,250 | 5,317 |
| Depreciation and amortization | — | 68 | — | 97 | 78 |
| Net cash from operating activities | (1,495) | (981) | — | (20,292) | (17,308) |
| Purchases of property and equipment | — | 306 | — | — | 4 |
| Net cash from investing activities | (276,000) | 402 | — | — | (4) |
| Proceeds from issuing common stock | 270,480 | — | — | 147 | — |
| Net cash from financing activities | 277,992 | 150 | — | 15,147 | 20,305 |
| Net change in cash | 497 | (430) | — | (5,145) | 2,993 |
- † Share count changed about 173x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| AEON Biopharma | 3,431 | not reported | (3,698)* | 49.9M | 0.9 quarters | 10-QJun 30, 2026 |
| GT Biopharma | 4,960 | not reported | (4,260)* | 45.1M | 1.2 quarters | 10-QJun 30, 2026 |
| Biovie | 8,977 | not reported | (4,122)* | 7.5M | 2.2 quarters | 10-KJun 30, 2026 |
| TherapeuticsMD | 9,189 | not reported | not reported | 11.6M | — | 10-QJun 30, 2026 |
| Oncotelic Therapeutics | 186 | 250 | (92)* | 457.5M | 2.0 quarters | 10-QJun 30, 2026 |
| Talphera | 742 | not reported | (3,924)* | 51.9M | 4.4 quarters | 10-QJun 30, 2026 |
| Artelo Biosciences | 4,198 | not reported | (5,033)* | 4.6M | 0.8 quarters | 10-QJun 30, 2026 |
| Bioxytran | 177 | not reported | (350)* | 114.7M | 0.5 quarters | 10-QJun 30, 2026 |
| Processa Pharmaceuticals | 196 | not reported | (1,996)* | 2.8M | 0.1 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.